VANCOUVER, British Columbia
MENLO PARK, Calif.
Feb. 28, 2013
/PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") is pleased to announce the appointment of Mr.
John K. Bell
to the company's Board of Directors.
John K. Bell
, is Chairman of Onbelay Capital Inc., a Canadian based private equity Company with principal investments in Telematics and auto parts manufacturing (for past 5 years). Prior to that, from 1996 to 2005, Mr. Bell was CEO and owner of Polymer Technologies Inc., an automotive parts manufacturer. Prior to that, from 1977 to 1995, Mr. Bell was founder and owner of Shred-Tech Limited a global manufacturer and supplier of industrial shredders and mobile document shredders. Mr. Bell served as interim CEO and director of ATS Automation Tooling Systems in 2007. Mr. Bell is a director of BSM Wireless, Strongco Corporation, and the Royal Canadian Mint. Mr. Bell is National secretary and board member of The Crohns and Colitis Foundation of
. Mr. Bell is past Chairman of Waterloo Regional Police, Cambridge Memorial Hospital,
's Technology Triangle accelerator network and The Region of Waterloo prosperity counsel. Mr. Bell is a graduate of
Ivey School of Business, a Fellow of the institute of Chartered Accountants of
, a graduate of the Institute of Directors Program of
and the owner's president program at
and International marketing program at Oxford.
"We are delighted to have
join the DelMar Board. In addition to his extensive financial and accounting background, John's operating experience will be invaluable as we continue to advance our business. John's skill set and experience complement DelMar's focus on developing and commercializing proven cancer therapies in new orphan drug indications," commented
, President & CEO of DelMar.
About DelMar Pharma
Del Mar Pharmaceuticals was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The Company's lead asset, VAL-083, is currently undergoing clinical trials in
the United States
as a potential treatment for refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. VAL-083 benefits from extensive clinical research sponsored by the US National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in
. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action.
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.